Cancer
Conditions
Interventions
None listed
Sponsors
Department of Drug Development and Regulatory Science, Faculty of Pharmacy, Keio University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. ambulatory cancer patients on treatment over 20 years old (not matter the type of cancer). 2. patients starting or increasing basal strong opioids (morphine, oxycodone, fentanyl, methadone, tapentadol, hydromorphone). 3. patients expected to survive for >6 months. 4. patients with ECOG Performance Status 0 - 1. 5. patients who have given their written consent.
Exclusion criteria
Exclusion criteria: 1. patients who are schduled for receiving radiotherapy for pain relief during observation period. 2. patients who are schduled for hospitalization or receiving surgery during observation period. 3. patients who introduce or increase strong opioids within 6 days after receive highly or moderately emetrogenic anticancer drug. 4. patients who are ineligible for measuring activity intensity due to comorbidity. 5. inappropriate patients for this study judged by research collaborator or physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in activity intensity before and after introducing or increasing of strong opioids, using METs(Metabolic equivalents) per day measured with wearable accelerometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in the number of steps per day before and after measured with wearable accelerometer. 2. Changes in SF-36 summary score and 8 subscales before and after. 3. Changes in VAS-Pain score before and after. | — |
Countries
Japan
Contacts
Public ContactHisashi Urusihara
Faculty of Pharmacy, Keio University Department of Drug Development and Regulatory Science
Outcome results
None listed